Sofinno­va-backed Abi­vax touts longer term mid-stage da­ta in ul­cer­a­tive col­i­tis

Two months af­ter Abi­vax con­vinced Sofinno­va to bankroll sev­er­al mid-stage stud­ies of its lead drug — ABX464 — with a €12 mil­lion stock pur­chase, the Paris-based biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER